Liquidia Can Launch Yutrepia Lung-Disease Drug, a Blow to UTC

Liquidia Corp. can launch its Yutrepia lung-disease drug after a Delaware federal judge agreed to remove part of his 2022 judgment blocking final approval, a blow to United Therapeutics Corp. and its blockbuster rival, Tyvaso.

“Invalid patents cannot be infringed,” Judge Richard G. Andrews wrote in an opinion issued Thursday in the US District Court for the District of Delaware.

Liquidia shares gained as much as 6.4% in postmarket trading.

Andrews granted Liquidia’s motion for post-judgment relief and vacated the final decision’s third and fourth paragraphs, which had blocked the US Food and Drug Administration’s approval of Yutrepia until the ...